{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 36 of 60', 'Table 11-1', 'Safety Laboratory Test Panels', 'Serum Chemistry', 'Hematology', 'Urinalysis', 'Glucose', 'Hemoglobin', 'Leukocyte esterase', 'Blood urea nitrogen', 'Erythrocytes', 'Nitrite', 'Creatinine', 'Mean corpuscular volume', 'Urobilinogen', 'Sodium', 'Platelets', 'Urine protein', 'Potassium', 'Reticulocytes', 'pH', 'Calcium', 'Leukocytes', 'Urine blood', 'Chloride', 'Differential (absolute and percent):', 'Specific gravity', 'Magnesium', 'Eosinophils', 'Urine ketones', 'Bicarbonate', 'Basophils', 'Urine bilirubin', 'Inorganic phosphate', 'Neutrophils', 'Urine glucose', 'Total and direct bilirubin', 'Lymphocytes', 'Alkaline phosphatase', 'Monocytes', 'Aspartate transaminase', 'Coagulation Studies', 'Alanine transaminase', 'Activated partial thromboplastin time', 'Amylase', 'Prothrombin time', 'Lipase', 'Prothrombin time International', 'Gamma-glutamyl transferase', 'Normalized Ratio', 'Protein', 'Albumin', 'Creatine kinase', 'Total cholesterol', 'Lactate dehydrogenase', 'Note: Haptoglobin may be analyzed if judged to be clinically appropriate by the investigator.', 'a', 'If urinalysis results are positive for leukocyte esterase, nitrite, protein, or blood, microscopic examination of', 'urine will be performed, and results will be provided for leukocytes, erythrocytes, crystals, bacteria, and casts.', 'b', 'If blood urea nitrogen cannot be collected, urea may be substituted.', 'Pregnancy (B-human chorionic gonadotropin) Tests for female subjects: All female subjects must', 'have a serum pregnancy test at screening. Serum pregnancy tests will be performed at the study', 'site and analyzed at the central laboratory. Urine pregnancy tests will either be performed and', 'analyzed at the site or, when there is no clinic visit scheduled, at home by using a home kit', 'provided by the site. Results will be reported to the site by telephone. The urine pregnancy test', 'on Day 1 must be negative before the first dose of study drug. Additional pregnancy tests may be', 'required according to local regulations and/or requirements.', 'FSH: Blood samples for FSH will be measured as needed for any suspected postmenopausal', 'female with at least 12 months of continuous spontaneous amenorrhea. Serum FSH levels must', 'be in the postmenopausal range as determined by the laboratory performing the test.', 'CFTR Genotype (Screening Period Only): CFTR genotyping will be performed for all subjects.', 'If the screening CFTR genotype result is not received before randomization, a previous CFTR', 'genotype laboratory report may be used to establish eligibility. Subjects who have been', 'randomized and whose screening genotype does not confirm study eligibility must be', 'discontinued from the study (Section 9.9).', 'Additional Evaluations: Additional clinical laboratory evaluations will be performed at other', 'times if judged to be clinically appropriate.', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 37 of 60', 'For the purposes of study conduct and unless noted otherwise, only laboratory tests done in the', 'central laboratory may be used. Local laboratories may be used at the discretion of the local', 'investigator for management of urgent medical issues. If a local laboratory test value is found to', 'be abnormal and clinically significant, it will be verified by the central laboratory as soon as', 'possible after the investigator becomes aware of the abnormal result. If it is not possible to send', 'a', 'timely specimen to the central laboratory (e.g., the subject was hospitalized elsewhere), the', 'investigator may base the assessment of an AE on the local laboratory value.', '11.5.3', 'Physical Examinations and Vital Signs', 'A PE of all body systems and vital signs assessments will be performed at screening and select', 'study visits (see Table 3-1 and Table 3-2). At other visits, symptom-directed PEs and', 'symptom-directed vital sign assessments will occur at any time if deemed necessary by the', 'investigator or healthcare provider.', 'A complete PE includes a review of the following systems: head, neck, and thyroid; eyes, ears,', 'nose, and throat (EENT); respiratory; cardiovascular; lymph nodes; abdomen; skin;', 'musculoskeletal; and neurological. Breast, anorectal, and genital examinations will be performed', 'when medically indicated. After screening, any clinically significant abnormal findings in PEs', 'will be reported as AEs.', 'Vital signs include blood pressure (systolic and diastolic), temperature, pulse rate, and', 'respiration rate. These will be assessed before dosing and following at least a 5-minute rest. A', 'consistent methodology should be used for repeat measurements of these parameters at a clinical', 'site.', '11.5.4', 'Pulse Oximetry', 'Pulse oximetry is a noninvasive measure of oxygen delivery to the tissues and has been', 'correlated with clinical status and lung function. Arterial oxygen saturation by pulse oximetry', 'will be assessed following at least a 5-minute rest and before study drug dosing. At visits when', 'study drug is taken at the site, pulse oximetry will be collected before study drug dosing', '(Section 9.6.1).', '11.5.5', 'Electrocardiograms', 'Standard 12-lead ECGs will be performed using a machine with printout according to the', 'schedule of assessments (Table 3-1 and Table 3-2). Additional standard 12-lead ECGs will be', 'performed at any other time if clinically indicated. Subjects will be instructed to rest for at least', '5 minutes before having an ECG performed.', 'The ECG traces will be manually read at the study site. A printout of the ECG traces will be', 'made for safety review by the investigator and maintained with source documentation. Clinically', 'significant ECG abnormalities occurring during the study through completion of study', 'participation will be recorded as AEs.', 'To ensure the safety of the subjects, a qualified individual at the study site will make', 'comparisons to baseline measurements. If the QTcF is increased by >60 msec from the baseline', 'or an absolute QTcF value is >500 msec for any scheduled ECG, 2 additional ECGs will be', 'performed approximately 2 to 4 minutes apart to confirm the original measurement. If either of', 'the QTcF values from these repeated ECGs remains above the threshold value (>60 msec from', 'baseline or >500 msec), a single ECG will be repeated at least hourly until QTcF values from', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}